Seminars in Nuclear Medicine
Volume 32, Issue 2 , Pages 84-91, April 2002

Somatostatin receptor imaging

  • Dik J. Kwekkeboom
    • ,
  • Eric P. Krenning

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Eric P. Krenning. MD, Department of Nuclear Medicine, Erasmus University Centre, Rotterdam, 3015GD Rotterdam, The Netherlands.

[111In-DTPA0]octreotide is a radiopharmaceutical with a great potential for the visualization of somatostatin receptor-positive tumors. The overall sensitivity of Somatostatin Receptor Imaging (SRI) to localize neuroendocrine tumors is high. In a number of neuroendocrine tumor types, as well as in Hodgkin's disease, inclusion of SRI in the localization or staging procedure may be very rewarding, either in terms of cost-effectiveness, patient management, or qulity of life. The value of SRI in patients with other tumors, like breast cancer, or in patients with granulomatous diseases, has to be established.

The development of Peptide Receptor Radionuclide Therapy (PRRT) is expected to stimulate peptide receptor imaging.

No full text is available. To read the body of this article, please view the PDF online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0001-2998(02)80026-5

doi:10.1053/snuc.2002.31022

Seminars in Nuclear Medicine
Volume 32, Issue 2 , Pages 84-91, April 2002

Article Tools